Visual Performance and Patient Satisfaction of Bilaterally Implanted Extended Depth of Focus Intraocular Lens:...

To evaluate visual performance, patient satisfaction, and spectacle independence in patients bilaterally implanted with AcrySof IQ Vivity intraocular lenses (IOLs) (Alcon Laboratories, Inc) during cataract or refractive lens exchange (RLE) surgery.

This multicenter, ambispective, non-interventional registry study was conducted in Europe, Australia, and New Zealand. At the first follow-up visit, occurring between 3 and 6 months after IOL implantation, binocular uncorrected and corrected distance visual acuities at distance (UDVA/CDVA), intermediate (UIVA/DIVA 66 cm), and near (UNVA/DNVA 40 cm) were evaluated using the logarithm of the minimum angle of resolution (logMAR) chart. Patient satisfaction, spectacle independence, visual disturbances, and device deficiencies were also assessed.

The final analysis included 885 patients, with 790 (89.3%) and 82 (9.3%) patients who underwent cataract and RLE, respectively, where approximately 30% had one or more ocular comorbidity. Mean ± standard deviation logMAR (Snellen) UDVA, UIVA, and UNVA were 0.012 ± 0.102 (∼20/20), 0.088 ± 0.118 (∼20/25), and 0.256 ± 0.154 (∼20/40) for the cataract cohort and -0.005 ± 0.088 (∼20/20), 0.054 ± 0.141 (∼20/25), and 0.213 ± 0.151 (∼20/32) for the RLE cohort, respectively. The proportion of patients reporting spectacle independence at distance, intermediate, and near was 87.9%, 77.6%, and 46.1% for the cataract and 86.6%, 79.3%, and 59.8% for the RLE cohorts. The majority of patients among the cataract (92.1%) and RLE (85.4%) cohorts were satisfied with their postoperative sight, whereas 91.8% of the cataract and 84.1% of the RLE cohort reported no visual disturbances. No device deficiencies were reported.

In this real-world study, patients bilaterally implanted with AcrySof IQ Vivity IOLs demonstrated good visual performance and the majority reported spectacle independence for distance to intermediate, high visual satisfaction, and low levels of visual disturbances across both cohorts, despite approximately 30% who reported 1 or greater ocular comorbidity. [.